Kairos Pharma Ltd [AMEX: KAPA] jumped around 0.48 points on Tuesday, while shares priced at $1.17 at the close of the session, up 70.78%.
Compared to the average trading volume of 887.64K shares, KAPA reached a trading volume of 241295142 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Kairos Pharma Ltd [KAPA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KAPA shares is $8.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KAPA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 2.60, with the Price to Cash per share for the same quarter was set at 0.21.
How has KAPA stock performed recently?
Kairos Pharma Ltd [KAPA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 76.20. With this latest performance, KAPA shares gained by 105.26% in over the last four-week period, additionally plugging by 20.62% over the last 6 months – not to mention a drop of -23.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KAPA stock in for the last two-week period is set at 79.66, with the RSI for the last a single of trading hit 0.1803, and the three-weeks RSI is set at 0.1233 for Kairos Pharma Ltd [KAPA]. The present Moving Average for the last 50 days of trading for this stock 0.6422, while it was recorded at 0.8022 for the last single week of trading, and 1.1705 for the last 200 days.
Kairos Pharma Ltd [KAPA]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -79.52%, with Return on Assets sitting at -79.52%.
Earnings analysis for Kairos Pharma Ltd [KAPA]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KAPA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kairos Pharma Ltd go to -24.45%.
Insider trade positions for Kairos Pharma Ltd [KAPA]
There are presently around $9.36%, or 17.75% of KAPA stock, in the hands of institutional investors.
